Document is current
Any future updates will be listed below
-
Authors
Braun, Till
Rade, Michael
Merz, Maximilian https://orcid.org/0000-0002-2805-5973
Klepzig, Hanna
Große, Florian https://orcid.org/0000-0002-5458-3788
Fandrei, David https://orcid.org/0009-0006-4014-6030
Pham, Nhu-Nguyen https://orcid.org/0000-0001-6483-8062
Kreuz, Markus
Kuhn, Christina Katharina
Kuschel, Florian
Löffler, Dennis
Meinel, Jörn
Heger, Eva https://orcid.org/0000-0001-7625-5139
Schweinsberg, Viola https://orcid.org/0000-0003-1375-2386
Pflug, Natali
Platzbecker, Uwe https://orcid.org/0000-0003-1863-3239
Hallek, Michael https://orcid.org/0000-0002-7425-4455
Holtick, Udo
Köhl, Ulrike
Scheid, Christof
Reiche, Kristin https://orcid.org/0000-0002-4452-4872
Herling, Marco
Richardson, Tim https://orcid.org/0009-0006-3588-6376
-
Funding
Funding for this research was provided by:
José Carreras Leukämie-Stiftung (DJCLS 08 R_2023, DJCLS 01 R_2023)
Wilhelm Sander-Stiftung (2023.084.1)
Massachusetts Department of Fish and Game (PF1028/1-1)
Innovative Medicines Initiative (853988)
- License Information
-
More Information
Article History
Received: 20 October 2024
Accepted: 7 January 2025
First Online: 21 February 2025
Competing interests
: M.M. gave advisory boards and received honoraria and research support from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks, Sanofi and Takeda. U.H. received consultant and/or speaker fees from Bristol-Myers Squibb, Gilead, Janssen, Miltenyi Biotec and Novartis. C.S. gave advisory boards and received honoraria from Amgen, Abbvie, Bristol-Myers Squibb, Janssen, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline Menarini and Takeda, and received research support from Janssen and Takeda. U.K. received consultant and/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, CGT manufacturing: Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. M. Herling gave advisory boards and received honoraria from Abbvie, Beigene, Jazz, Janssen, Stemline Menarini and Takeda, and received research support from EDO-Mundipharma, Janpix, Novartis and Roche. The other authors declare no competing interests.
